← SynDRA
ADAVOSERTIB
SynDRA canonical compound SYN0028842 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | WEE1 |
|---|
| Mechanism of action | WEE1 kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- WEE1 kinase inhibitor
- WEE1 INHIBITOR
- Serine/threonine-protein kinase WEE1 inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- AAK1
- NEK2
- PDXK
- PDGFRB
- PDGFRA
- PASK
- PAK6
- PAK4
- PAK2
- PAICS
- OPA1
- OLA1
- NUAK2
- NTRK3
- NTRK2
- NTRK1
- NQO2
- NLK
- NEK9
- PEBP1
- PFKP
- PGRMC1
- PLK4
- PRKAR2A
- PRKAG2
- PRKAG1
- PRKACG
- PRKACB
- PRKACA
- PRKAA1
- PLK1
- PHKG2
- PKN3
- PKN2
- PKN1
- PKMYT1
- PIP4K2C
- PIM2
- PIM1
- NEK3
Cross-references
Synonyms
- AZD-1775
- ADAVOSERTIB (MK-1775)
- ADAVOSERTIB £¨MK-1775£©
- AZD1775
- MK-1775
- MK1775
- MK 1775
- UNII-K2T6HJX3I3
- 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one
- K2T6HJX3I3
- 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one
- 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one
- AK-99219
- adavosertibum
- RefChem:109657
- DTXCID60164359
- MFCD17215200
- Adavosertib (MK-1775)
- Adavosertib (USAN)
- MK-1775(AZD-1775,Adavosertib)
- ADAVOSERTIB [USAN]
- Adavosertib; MK-1775; MK 1775
- C27H32N8O2
- 8X7
- Adavosertib (Standard)
- Kinome_2656
- ADAVOSERTIB [INN]
- Adavosertib; MK-1775
- ADAVOSERTIB [WHO-DD]
- MLS006011025
- GTPL7702
- orb1306538
- SCHEMBL1504444
- SCHEMBL29381006
- SCHEMBL30559444
- CHEBI:91414
- EX-A331
- GLXC-90201
- HMS3295K03
Look up ADAVOSERTIB in the interactive SynDRA portal →